See the news after the close. The new Congress is hell bent on bringing the stem cell bill back. Big question is - will ACTC be a recipient if it works and next - if they get the funding, do they have enough application oriented research that can generate some revenue in the short to medium term? Many biotech coys are nothing but great ideas (like dotcoms of '99) and zero revenue potential. If ACTC is one of those, no amount of funding can help. Remember the NVAX story - the coy had an amazing 2 week run during bird flu scare, but eventually back to $4 or something. Without a revenue generating product in next 12-18 months, all double digit growth stories are wishlists!
their strength is in their patents, which covers tech to extract stem cells without destroying/compromising the embryo. When legislation passes, with or without restrictions, ACTC will be in a valuable position to attract JVs and/or buyout offers...IMO.